Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | ESRRG | P62508 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3827799 | 0.96 | ESR1 (0.70) | ESR1CYP19A1ESR2PTGS2ESRRG | |
| SCHEMBL3810919 | 0.91 | ESR1 (0.74) | ESR1CYP19A1ESR2 | |
| SCHEMBL3812915 | 0.85 | ESR1 (0.92) | ESR1CYP19A1ESR2 | |
| SCHEMBL3813657 | 0.85 | ESR1 (0.64) | ESR1CYP19A1ESR2PTGS2ESRRG | |
| SCHEMBL4665812 | 0.83 | ESR1 (0.60) | ESR1CYP19A1ESR2PTGS2 | |
| SCHEMBL6767349 | 0.82 | ESR1 (1.00) | ESR1CYP19A1ESR2ESRRG | |
| SCHEMBL639683 | 0.82 | ESR1 (1.00) | ESR1CYP19A1ESR2ESRRG | |
| SCHEMBL6769196 | 0.82 | ESR1 (1.00) | ESR1CYP19A1ESR2ESRRG | |
| SCHEMBL5007980 | 0.81 | ESR1 (0.49) | ESR1CYP19A1ESR2PTGS2 | |
| SCHEMBL3810879 | 0.81 | ESR1 (0.67) | ESR1CYP19A1ESR2ESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-12-25 | — | — | US | disclosed |
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-12-25 | — | — | US | disclosed |
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-12-25 | — | — | US | disclosed |
| EP-1951043-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062067-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | ESR1 4/4885CYP19A1 7/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.